Medexus Pharmaceuticals (TSE:MDP) Reaches New 12-Month High – Here’s What Happened

Medexus Pharmaceuticals Inc. (TSE:MDP)’s stock price hit a new 52-week high during trading on Friday . The company traded as high as C$3.41 and last traded at C$3.28, with a volume of 19378 shares traded. The stock had previously closed at C$3.25.

Analysts Set New Price Targets

Several research firms have issued reports on MDP. Raymond James upgraded shares of Medexus Pharmaceuticals from a “market perform” rating to an “outperform” rating and upped their price target for the company from C$3.00 to C$4.00 in a research report on Wednesday, November 20th. Leede Financial set a C$8.25 target price on Medexus Pharmaceuticals and gave the company a “speculative buy” rating in a report on Monday, September 30th. Finally, Alliance Global Partners raised Medexus Pharmaceuticals to a “strong-buy” rating in a research note on Monday. Three analysts have rated the stock with a buy rating and three have given a strong buy rating to the company’s stock. According to MarketBeat.com, the stock has an average rating of “Strong Buy” and an average target price of C$5.25.

Medexus Pharmaceuticals Price Performance

The company has a market capitalization of C$80.46 million, a P/E ratio of 65.60 and a beta of 1.96. The company has a 50 day moving average of C$2.58 and a 200-day moving average of C$2.40.

About Medexus Pharmaceuticals

Medexus Pharmaceuticals Inc operates as a specialty pharmaceutical company in Canada and the United States. The company focuses on the therapeutic areas comprising oncology, hematology, rheumatology, auto-immune diseases, allergy, and dermatology. Its primary products are IXINITY, an intravenous recombinant factor IX therapeutic for use in patients 12 years of age or older with hemophilia B; Rasuvo and Metoject, a formulation of methotrexate designed to treat rheumatoid arthritis and other auto-immune diseases; Rupall, a prescription allergy medication; and Gleolan, an optical imaging agent indicated in patients with glioma as an adjunct for the visualization of malignant tissue during surgery.